Dr. Jeffrey Trent on the Melanoma Dream Team

Video

In Partnership With:

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute (TGen), discusses the Stand Up to Cancer (SU2C)-Melanoma Research Alliance (MRA) Dream Team.

The SU2C-MRA Dream Team focuses on investigating the utility of personalized targeted therapies and therapy identification in specific subgroups of patients with melanoma, such as BRAF wild-type. At TGen, researchers primarily focus on genomic information, looking at both hereditary information and genetic changes in cancer cells, to examine differences and impact clinical decision-making, Trent explains.

The SU2C-MRA Dream Team is three years into developing approaches, infrastructure, technologies, and reporting associated with FDA regulatory approvals. Thus far, Dream Team researchers have examined approximately seven patients out of more than 100 enrolled in the trial, Trent says.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD